SPRY · CIK 0001671858 · operating
ARS Pharmaceuticals is a biopharmaceutical company focused on developing treatments for severe allergic reactions, specifically anaphylaxis. The company's primary product candidate is Neffy, a needle-free intranasal epinephrine nasal spray designed as a rescue medication for individuals experiencing Type I severe allergic reactions. The formulation delivers a low dose of epinephrine without requiring a needle, positioning it as an alternative to traditional auto-injectors for emergency allergy treatment.
The company serves multiple stakeholder groups including healthcare professionals, patients, and caregivers who manage severe allergies. Founded in 2015 and based in San Diego, California, ARS Pharmaceuticals operates with a team of 162 full-time employees. The company is incorporated in Delaware and trades on the Nasdaq under the ticker SPRY.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $0.08 | $0.08 | +114.0% | |
| 2023 | $-0.57 | $-0.57 | +34.5% | |
| 2022 | $-0.87 | $-0.87 | — | |
| 2021 | — | — | — |